Brain tumour clinical trial title

Translocator Protein Expression in Transforming Gliomas

Brain tumour type

Anaplastic astrocytoma,  Anaplastic glioma,  Anaplastic oligodendroglioma,  Astrocytoma,  Glioblastoma,  Glioma, 



Non-randomised non-blinded pilot study. In gliomas, experimental and postmortem studies have shown increased expression of translocator protein (TSPO) within the high­grade tumours. Recent studies support the idea that TSPO expression may serve as a biomarker for malignant transformation in these brain tumours and help in differentiating low and high­grade tumours. In this study, PET imaging - with the radiotracer PK11195, a selective radioligand for TSPO – will be compared with perfusion MRI and standard diagnosis by histology to test the hypothesis that malignant transformation of gliomas is accompanied by early increases of TSPO expression, detectable by PK11195 PET imaging; and allow us to calculate the sample size required for conducting a larger study to evaluate the role of TSPO imaging in early detection of glioma malignant transformation as well as its relation with disease progression. Such information could provide important insights into the biology of this common brain tumour, and could be used to guide future treatment, monitor response and help predict outcomes.

Date added: 16th August 2015

Open/Closed: Open

Trial ends: July 2016


University of Manchester

Contact details

Mr Jonathan Bevan :
Wolfson Molecular Imaging Centre
27 Palatine Road
M20 3LJ
Telephone: 0161 275 0010

Find on Google maps »